MONDAY, SEPTEMBER 26, 2016

More Flublok influenza vaccine expected this year over last

Protein Sciences Corp. recently announced that it will produce up to 500,000 doses of its Flublok influenza vaccine for the 2014-2015 season.

The company said the vaccines will be available earlier and have a wider distribution than last year. The first Flublok doses are expected to be available in September.

"Last year healthcare professionals wanted Flublok available sooner and from more access points," Wayne Hachey, the head of government and clinical affairs at Protein Sciences, said. "We are pleased to give them just that."

ASD Specialty Healthcare and its Besse Medical and Oncology Supply divisions will also join FFF Enterprises as distributors of Flublok this year.

"We are excited to add ASD Specialty Healthcare and its Besse Medical and Oncology Supply divisions to our distribution network," Manon Cox, the president and CEO of Protein Sciences, said. "Both FFF and ASD offer fast, reliable delivery of Flublok to healthcare professionals nationwide."

Flublok, approved in 2013 by the U.S. Food and Drug Administration, is the world's first recombinant protein-based vaccine for influenza.

Flublok currently has FDA approval for people ages 18-49, though Protein Sciences has applied to have it approved for patients 50 years or older and expects it to be available for the 2014-2015 season.